Citigroup upgraded shares of Tandem Diabetes Care (NASDAQ:TNDM – Free Report) from a neutral rating to a buy rating in a research report released on Wednesday morning, Marketbeat reports. Citigroup currently has $57.00 price target on the medical device company’s stock, up from their previous price target of $40.00. Several other analysts have also recently […]